Active Biotech AB Interim Report January – June 2013

Events during January – June 2013:

· positive results from Phase IIa study of laquinimod in active lupus nephritis
· Teva plans continued clinical development of laquinimod for the treatment of lupus nephritis
· data presented at AAN showed a slower disability progression for multiple sclerosis patients who commenced early treatment with laquinimod compared with delayed treatment  
· analysis plan for Phase III trial updated; primary PFS analysis expected at the same time as first interim overall survival analysis in 2014
· Phase II follow-up study shows an impact of tasquinimod on bone metastases as measured by
Bone Scan Index (BSI); results presented at ASCO
· improved overall survival in a subgroup of renal cell cancer patients in the Phase II/III study; results presented at ASCO

57-57 (paquinimod)            
· clinical trial in systemic sclerosis concluded, evaluation under way

· patent applications filed

               Jan – Jun Jan – Dec
 (MSEK)       2013       2012    2012
  •      Net sales
            5.0          96.6   227.9
  •      Operating loss
      -156.5       -120.6  -163.2
  •      Net loss
      -159.2       -123.5  -175.0
  •      Earnings per share (SEK)
        -2.18         -1.79    -2.54
  •      Cash and cash equivalents (MSEK)
        389.1         383.7    216.7

  For further information, please contact:

  Tomas Leanderson, President and CEO
  Tel: +46 (0)46-19 20 95    
  Hans Kolam, CFO     
  Tel: +46 (0)46-19 20 44      

  Active Biotech AB (Corp. Reg. No. 556223-9227)
  Box 724, SE- 220 07 Lund
  Tel: +46 (0)46-19 20 00 
  Fax: +46 (0)46-19 11 00

  This report is also available at   

Active Biotech AB Interim Report January – June 2013

This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.

Source: Active Biotech via Thomson Reuters ONE